Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By Greater Fool (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Buffered

% of readers think this story is Fact. Add your two cents.


.
  By Guest Blogger Sinan Terzioglu
.

Buffer ETFs, also known as defined-outcome ETFs, have gained popularity for their ability to provide some downside protection on an underlying index while still allowing participation in potential market gains. This feature makes them appealing to investors who are wary about market volatility. However, despite their initial appeal, long-term investors should avoid these products.

Buffer ETFs utilize complex options strategies to set a position that defines an outcome over the next 12 months. This outcome includes a specific threshold such as a 10% or 15% decline, which the index must fall before the ETF incurs losses. At the same time, the ETF can benefit from gains up to a certain limit, like 10% or 15%, beyond which no additional gains will be realized.

Buffered strategies are not a recent innovation as they have been used in products sold by insurance and mutual funds companies for several years. However, the ETF versions have become widely available as US and Canadian providers have introduced dozens of buffer ETFs tracking various equity indices such as the S&P 500, Nasdaq 100 and MSCI EAFE Index. Today, there are over 250 such funds, with approximately US$50 billion in assets.

The protection provided by buffer ETFs is limited and extreme market downturns can still result in substantial losses so investors need to be aware of the specific terms and conditions of each ETF, as these can vary widely. For example, if a buffer ETF provides downside protection of 15% and the underlying index drops by 35% during the outcome period, the investor could be down as much as 20%. Buffer ETFs can be traded at any time, but they need to be held for the entire one-year outcome period to function as intended.

One of the first buffer ETFs, the Innovator US Equity Buffer ETF (PAPR), was launched in April 2019. PAPR aims to define the outcome of the S&P 500 starting April 1 each year for the following 12 months, providing protection against the first 15% of downside. However, holders of PAPR sacrifice potential upside returns beyond approximately 14.50%. PAPR does not pay dividends as options are written on the price return of the S&P 500 only, not the total return. The partial downside hedge and upside cap are reset annually, so investors who purchase this ETF at any other time than the annual reset day of April 1 may have very different protection and buffer zones.

Over its initial outcome period from April 1, 2019, to March 31, 2020, the S&P 500 had a total return of -8.04%, while PAPR lost 0.73%. This period included the fastest ever 30%+ decline in global equity markets from mid-February, 2020 to March 23, 2020, due to the onset of the COVID-19 pandemic. As expected, holders of PAPR over the entire outcome period experienced less of a drawdown than the S&P 500.

However, an investor who continued to hold PAPR through the following reset period starting on April 1, 2020, and held for the next 12 months would have experienced a significant amount of underperformance relative to the S&P 500 due the cap on the upside. From April 1, 2020, to March 31, 2021, the S&P 500 returned a total of 63.79%, while PAPR returned 14.51%.

The primary drawback of buffer ETFs is their asymmetrical return profile. PAPR, for instance, protects against the first 15% of losses for the S&P 500 but caps upside returns at approximately 14.50%. This means that if an investor holds for the full one-year outcome period and the market falls 50%, they could lose up to 35.50% while the maximum gain would be less than half the potential loss. Therefore, holders of buffer ETFs are more likely to miss out on upside returns than benefit from the limited downside protection. This is evidenced by PAPRs average annual return of 7.17% since inception, which is less than half the average annual return of the S&P 500 over the same period.

In summary, while buffer ETFs can offer some protection in volatile markets, they are not suitable for long-term investors due to their complexity, limited downside protection, capped upside and higher costs.

A more effective strategy for reducing downside risk and achieving solid risk-adjusted returns over the long-term is to maintain a balanced and globally diversified portfolio, which provides a buffer without restricting the upside potential of equity holdings.

Sinan Terzioglu, CFA, CIM, is a financial advisor with Turner Investments, Private Client Group, Raymond James Ltd.  He served as vice-president of RBC Capital markets in New York City and VP with Credit Suisse in Toronto.


Source: https://www.greaterfool.ca/2024/09/24/buffered/


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.


LION'S MANE PRODUCT


Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules


Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.



Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.


Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

MOST RECENT
Load more ...

SignUp

Login

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.